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Blood loss remains a major concern during surgery and can increase the morbidity of
the intervention. The use of topical haemostatic agents to overcome this issue there-
fore becomes necessary. Fibrin sealants are promising haemostatic agents due to
their capacity to promote coagulation, but their effectiveness and applicability need
to be improved. We have compared the haemostatic efficacy of a novel nanostruc-
tured fibrin‐agarose hydrogel patch, with (c‐NFAH) or without cells (a‐NFAH), against
two commercially available haemostatic agents in a rat model of hepatic resection.
Hepatic resections were performed by making short or long incisions (mild or severe
model, respectively), and haemostatic agents were applied to evaluate time to
haemostasis, presence of haematoma, post‐operative adhesions to adjacent tissues,
and inflammation factors. We found a significantly higher haemostatic success rate
(time to haemostasis) with a‐NFAH than with other commercial haemostatic agents.
Furthermore, other relevant outcomes investigated were also improved in the
a‐NFAH group, including no presence of haematoma, lower adhesions, and lower
grades of haemorrhage, inflammation, and necrosis in histological analysis. Overall,
these findings identify a‐NFAH as a promising haemostatic agent in liver resection
and likely in a range of surgical procedures.
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Uncontrolled haemorrhage remains an important intraoperative
complication that may change patient follow‐up after major surgical
interventions and is responsible for high rates of mortality and morbid-
ity and longer hospitalization duration (Brustia, Granger, & Scatton,
2016). In particular, hepatic resection often requires perioperative
transfusion due to intraoperative blood loss. Despite improvements
in existing surgical, anaesthesia preassessment and/or other perioper-
ative interventions (suturing, cauterization, patient positioning, and
use of special equipment such as water jet, radiofrequency ablation,
or cavitron ultrasonic surgical aspirator), the reduction of bleeding
during hepatic surgery remains transitory or incomplete (Berrevoet &
Hemptinne, 2007; Brustia et al., 2016; Chouillard, Gumbs, &
Cherqui, 2010; Eeson & Karanicolas, 2016; Smyrniotis, Farantos,
Kostopanagiotou, & Arkadopoulos, 2005; Tympa et al., 2012; Zhu
et al., 2015). Accordingly, topical haemostatic agents are usually
required to prevent intraoperative or post‐operative blood loss (Eeson
& Karanicolas, 2016; Moggia et al., 2016).
Several haemostatic agents approved by Food and Drug Adminis-
tration have been developed to maintain haemostasis in multiple
surgical procedures. Topical haemostatic agents can be classified
according to their composition in matrix‐based, fibrin and/or
thrombin‐based and combined products (matrix + fibrin and/or
thrombin‐based haemostatic agent). Matrix‐based products form a
barrier that interrupt blood flow facilitating clot formation (e.g.,
Gelfoam, Hemopatch) whereas fibrin and/or thrombin‐based products
provide factors and compounds that promote generation of fibrin clots
(e.g., Tissucol, Evicel). Combined products (e.g., Tachosil, Evarrest)
seem to achieve better results (Brustia et al., 2016).
Fibrin sealant derived from human plasma has become a popular
haemostatic agent due to its capacity to imitate and promote the final
step of the coagulation cascade (Mankad & Codispoti, 2001;
MOSESSON, SIEBENLIST, & MEH, 2006). Furthermore, fibrin sealant
is the only Food and Drug Administration clinical material approved
as a haemostatic sealant and adhesive agent for therapeutic use.
Despite recent advances in the field, however, overall haemostatic
suitability in terms of effectiveness (time to haemostasis), applicability,
or absence of rebleeding or undesired adhesion remains far from
perfect and could be further improved (Spotnitz, 2014).
We have previously developed a nanostructured fibrin and type VII
agarose hydrogel (NFAH) as a scaffolding biomaterial compatible with
multiple tissue models (Alaminos et al., 2006; Carriel et al., 2012,
2013; Carriel, Garzón, Campos, Cornelissen, & Alaminos, 2014;
Garzón et al., 2014; Sanchez‐Quevedo et al., 2007). This biomaterial
can be seeded with different cell types and has been characterized
as a substitute for cornea, oral mucosa, and nerve (Carriel et al.,
2017; Ionescu et al., 2011; Rodríguez et al., 2012). This stromal‐like
substitute is composed mainly of human plasma and shows high
flexible and elastic properties as well as mechanical strength
(Mosesson et al., 2006; Scionti et al., 2014). Moreover, fibroblasts
and other cell types can be seeded inside the scaffold with good
viability and function (Carriel et al., 2013).In the present study, we explored the haemostatic effectiveness of
NFAH, with and without seeded allogeneic fibroblasts, in a partial
hepatectomy rat model of short or long hepatic incision (mild or
severe hepatic resection, respectively). The performance of the acellu-
lar (a‐NFAH) or cellularized (c‐NFAH) scaffold was compared with two
commercially available haemostatic products commonly used in
multiple surgical procedures: a polyethylene glycol‐coated collagen
pad (PCC, Hemopatch®; Lewis, Ikeme, Olubunmi, & Kuntze, 2018)
and a fibrinogen/thrombin‐coated collagen pad (FTC, Tachosil®;
Rickenbacher, Breitenstein, Lesurtel, & Frilling, 2009).2 | MATERIALS AND METHODS
2.1 | Cell culture
Fibroblasts used in this study were isolated from Wistar rat dermal tis-
sue. Skin biopsies were thoroughly washed in phosphate‐buffered
saline (PBS) containing penicillin–streptomycin solution (Sigma‐
Aldrich, St. Louis, MO, USA), 20 μg/ml gentamicin, and 50 μg/ml van-
comycin (Normon Laboratories S.A., Madrid, Spain) and cut into pieces
of approximately 1 × 1 mm2. Twenty pieces were transferred to a
50‐ml conical centrifuge tube containing 5 ml of preheated 2‐mg/ml
collagenase solution (SERVA Electrophoresis GmbH, Heidelberg,
Germany) prepared in Dulbecco's modified Eagle's medium (Sigma‐
Aldrich). Samples were incubated on rotation for 16 hr at 37°C.
Digestion was neutralized by addition of Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum (Sigma‐Aldrich,
St. Louis, MO), 0.1‐mM non‐essential amino acids (Sigma‐Aldrich), 2‐
mM Glutamax (Gibco, Fisher Scientific, Pittsburgh, PA, USA), and
penicillin–streptomycin solution. Finally, the cell suspension was
pelleted, counted, plated in a 25‐cm2 flask, and grown in a humidified
incubator at 5% CO2 and 37°C.
Culture medium was changed every 2–3 days until the culture
reached 70–90% confluence. At this point, cells were harvested and
expanded until Passage 2. Finally, cells were cryopreserved in liquid
nitrogen until generation of the hydrogels.2.2 | Immunofluorescence
Fibroblasts were seeded onto glass coverslips (VWR, Radnor, PA, USA)
in 24‐well plates (Nalgene Nunc International, Rochester, NY, USA)
and incubated in a humidified incubator with 5% CO2 at 37°C. Once
confluent, coverslips were washed with PBS and fixed with 3.7%
formaldehyde (Sigma‐Aldrich) in PBS for 15 min at room temperature.
The coverslips were then washed three times with PBS, and cells were
permeabilized with 0.05% Triton X‐100 (Sigma‐Aldrich) for 15 min at
room temperature and blocked with PBS containing 1% bovine serum
albumin (Sigma‐Aldrich) for 30 min at 37°C. Subsequently, the cover-
slips were incubated for 30 min at 37°C with a 1:1,000 dilution of
an antivimentin antibody (VI‐10; ab20346 Abcam plc, Cambridge,
UK) diluted in PBS containing 0.1% bovine serum albumin. Coverslips
were then washed three times with PBS and incubated for 30 min at
666 CAMPOS‐CUERVA ET AL.37°C with the secondary antibody, an Alexa Fluor 594 anti‐mouse IgG
antibody (A11005; Thermo Fisher Scientific). Nuclei were stained and
mounted with ProLong™ Gold Antifade Mountant with DAPI
(P36931; Thermo Fisher Scientific). Fluorescent microscopy was per-
formed on a Nikon TiS microscope (Nikon Instruments, Amsterdam,
The Netherlands).2.3 | Karyotyping
For cytogenetic analysis, the karyotype with Bands‐G of the fibroblast
cell cultures was performed by the Andalusian Public Health System
Biobank. To carry out analysis, first, the cells are incubated in medium
supplemented with 0.1 mg/ml of colcemide for 4 hr. Later, they are
washed with PBS, trypsinized, and centrifuged. The pellet are resus-
pended in a hypotonic solution of KCl (0.075 mol/L), washed to remove
the cytoplasm, and the nuclei are fixed with methanol/acetic in a 3:1
ratio (vol/vol). Finally, the metaphases are resuspended in 1 ml of fixa-
tive and are fixed in slides. G bands with trypsin‐Giemsa (GTG) are
made, and a minimum of 20 metaphases are analysed for each cell line,
assigning a karyotype formula according to the International System of
Human Cytogenetic Nomenclature (McGowan‐Jordan, Simons, &
Schmid, 2016). The karyotypes are analysed using a microscope Leica
DM5500 and the Ikaros Karyotyping System (Metasystems).2.4 | Generation of the NFAH pad
The protocol for NFAH production is an adaptation of methods
described previously (Alaminos et al., 2006; Carriel et al., 2012; 2013;
2014; Garzón et al., 2014; Scionti et al., 2014). To obtain the volume
of fibrin‐agarose hydrogel (FAH) needed to coat a six‐well plate with
24 mm transwell inserts (3450; Corning Incorporated, Kennebunk,
ME, USA), a 30‐ml mixture was prepared as follows: 25 ml of human
plasma (Tebu‐bio, Le‐Perray‐en‐Yvelines, France), 0.5 ml of tranexamic
acid (Amchafibrin 500 mg, Rottapharm, Milan, Italy), and 2 ml of culture
medium, with or without fibroblasts, was placed into a 50 ml conical
tube. Subsequently, a solution containing 1.8 ml of 10% calcium chlo-
ride (B.Braun, Melsungen, Germany), 1.2‐ml PBS, and 1.5 ml of liquid
2.2% type VII agarose (Sigma‐Aldrich) was added. After mixing, 5 ml
of the resulting solution was poured into each transwell, and the plate
was left at 37°C for 2 hr. Once gelation was complete, the FAH was
covered with culture medium and maintained at 37°C for 24 hr (plates
remained in the incubator for a further 7 days when FAH contained
cells), prior to nanostructuration (Figure 1a).
Nanostructuration is a compression and dehydration process. This
technique preserves the fibrin structure while removing most of its
water content. As a consequence, rheological properties of FAH are
changed increasing elasticity and resistance (Ionescu et al., 2011). To
this purpose, FAH was placed between two extra‐thick western blot-
ting filter paper (88620; Thermo Fisher Scientific). Two 10‐μm nylon
net filters (NY‐1009000; Merck Millipore, Burlington, MA) were
positioned between the sample and the blotting paper to prevent
adherence. Rapidly, a flat glass surface of 0.25 kg is positioned onthe top for 1 min and 40 s for compression. The final acellular or
cellularized NFAH has a high density with approximately 80%
dehydration and a thickness of 50–60 μm.2.5 | Animal protocol and hepatic resection
Male Wistar rats (200–250 g) were distributed in two experimental
groups, according to the extension of tissue resection. The first short inci-
sion or mild experimental model (n = 20) includes two animal groups dis-
tributed in PCC (n = 10) and c‐NFAH (n = 10). The second long incision or
severe experimental model (n = 45) includes four animal groups distrib-
uted in PCC (n = 15), FTC (n = 10), c‐NFAH (n = 10), and a‐NFAH
(n = 10). Anaesthesia was induced by subcutaneous injection of 80‐mg/
kg ketamine and 10‐mg/kg xylazine and was maintained by isoflurane
inhalation. After abdominal shaving, animals underwent a longitudinal
laparotomy 1 cm below the xiphoid process in the craniocaudal direction,
leaving the hepatic median lobe exposed for the procedure. Hepatic
resection was performed in animals with an incision of 0.5 (short incision
or mild model) or 1.5 cm (long incision or severe model) in length.
All haemostatic agents were applied as round‐shaped pads of 12‐mm
diameter for the short incision and 24 mm for the long incision. Time to
haemostasis was defined as the time needed for the arrest of free blood
leakage after application of the haemostatic agent. The timer was started
at the moment of application of the haemostatic agent over the hepatic
surface and was stopped when a complete cessation of blood extravasa-
tion through the hepatic resection surface was achieved.
Immediately postrecovery, rats were housed in individually venti-
lated cages with free access to food and water. If animals required
analgesia, ketoprofen was administrated every 12 hr.
Rats were euthanized by cardiac puncture 24 hr after surgery to
evaluate post‐operative haemorrhage, presence of haematoma, migra-
tion of the haemostatic agent, and intra‐abdominal adhesion of the
haemostatic agent to adjacent intact tissues. Blood was also drawn
for the measurement of cytokines by Enzyme‐Linked ImmunoSorbent
Assay (ELISA). The grade of adhesion was determined by a score of 0–
2: 0, no adhesion; 1, thin adhesions separable by gravity; 2, thick adhe-
sions not separable by gravity.
Sections of hepatic tissue attached to the haemostatic agent were
fixed in 4% paraformaldehyde for histopathological analysis.
All procedures were performed according to “Guide for the Care
and Use of Laboratory Animals” published by Ministry of Agriculture,
Fisheries and Food (R.D. 53/2013, Law 32/2007) and European Com-
munities Council Directive 2010/63/UE. The protocol was approved
by the Research Ethics Committee of University Hospital Virgen
Macarena and Virgen del Rocío (internal reference: 1131‐N‐15).2.6 | ELISA
Blood samples were collected in EDTA tubes (BD Bioscience, NJ,
USA), centrifuged at 1,480 × g for 5 min and stored at −20°C in small
volumes to avoid repeated freeze–thaw cycles. The following com-
mercial ELISA kits were used for cytokine analysis: rat C‐reactive
FIGURE 1 Generation and application of
nanostructurated fibrin‐agarose hydrogel
(NFAH). (a) Generation scheme of NFAH. (b)
Sequential NFAH application on rat hepatic
resection. Images show hepatic incision,
wound exposition (1–3), NFAH application,
and final positioning (4–6). (c,d) Time to
haemostasis for rats subjected to (c) short and
(d) long hepatic incision treated with different
haemostatic agents (N = 10). Data represent
mean ± SEM. Mann–Whitney U test was used
for experiments with two groups, whereas the
analysis between more than two groups was
performed by Kruskal–Wallis analysis of
variance test followed by Dunn's post hoc test
(**p < 0.01) [Colour figure can be viewed at
wileyonlinelibrary.com]
CAMPOS‐CUERVA ET AL. 667protein (CRP) ELISA Kit (Catalog N° ELR‐CRP, RayBiotech Inc.,
Norcross, GA, USA), rat interleukin 1 beta (IL‐1β) ELISA Kit (Catalog
N° E‐EL‐R0012, Elabscience, Houston, TX, USA), and rat tumour
necrosis factor alpha (TNF‐α) ELISA Kit (Catalog N° CSB‐E11987R,
Cusabio Technology LLC, Houston, TX, USA).2.7 | Microscopy analysis
Paraformaldehyde‐fixed paraffin‐embedded blocks of liver tissue were
cut at a thickness of 4 μm, and sections were stained with the
Trichrome Stain (Masson) Kit (Catalog N° HT15‐1KT, Sigma‐Aldrich)
and haematoxylin–eosin (Catalog N° GHS316 and HT110116,
Sigma‐Aldrich), by standard methods. Sectioned liver samples were
analysed by investigators blinded to the treatment groups.Histological variables were studied by microscopic analysis and
categorized as shown in Table 1.
2.8 | Statistical analysis
Based on our preliminary data, the sample size was calculated to
detect a significant effect d = 0.55, with a power of 80% at a level
of significance of 5%. This requires a minimum of 10 animals per group
(https://www.anzmtg.org/stats/PowerCalculator/PowerANOVA).
Data are presented as mean ± SEM. Significance was determined
using the Mann–Whitney U test or the Kruskal–Wallis analysis of var-
iance test with Dunn's post hoc multiple comparison test. Differences
were considered significant at p ≤ 0.05. All statistical analyses were
performed using GraphPad Prism 7.0 (GraphPad Software Inc., San
Diego, CA).
TABLE 1 Categorization criteria for histological variables studied by microscopic analysis
Variable
Category
Absent Mild Moderate Intense
Haemorrhage Groups of erythrocytes that come




Area of haemorrhage: 1‐to 2.5‐mm
diameter and less than ×40 hpf
of depth
Area of haemorrhage: >2.5‐mm
diameter or more than ×40
hpf of depth
Inflammation — Few granulocytes Some infiltrates, perivascular cuffing Massive infiltration
Necrosis — 0.1–0.4 hpf 0.5–1.2 hpf >1.2 hpf
Note. hpf: high‐power fields.
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3.1 | NFAH has a superior haemostatic effect
NFAH pads comprise a nanostructured fibrin‐type VII agarose hydro-
gel with (c‐NFAH) or without embedded (a‐NFAH) cells (Figure 1a).
To prepare the cellularized solution, we used 150,000 thawed rat
fibroblasts (at Passage 2) per millilitre of final volume. Fibroblasts
showed robust vimentin expression and a normal karyotype, as
expected for healthy proliferating fibroblasts (Figure S1).
We first studied the haemostatic effect of c‐NFAH in a mild model
of hepatic resection (short, 0.5‐cm incision). The c‐NFAH pad was pre-
pared as a round‐shaped patch of 12 mm and was placed onto the
bleeding surface (Figure 1b). Results showed that the effectiveness
of haemostasis was significantly greater with the c‐NFAH pad
than with the PCC pad (p < 0.05), with a mean time to haemostasis
of 2 ± 2 s (N = 10, range = 0–20) and 8.4 ± 2.6 s (N = 10, range = 5–
20), respectively (Figure 1c).
We next tested the haemostatic effect of the c‐NFAH pad in a
severe model of hepatic resection (long, 1.5‐cm incision). We also
included three additional treatment groups in this analysis: a‐NFAH,
to evaluate whether fibroblasts had a beneficial effect on the
haemostatic process; FTC, to compare the effect of c‐NFAH with
another fibrin‐based commercial haemostatic product; and PCC, to
compare the fibrin‐based products with a collagen‐based matrix.
Results showed that a‐NFAH presented the lowest time to
haemostasis at 2.4 ± 0.58 s (N = 10, range = 1–5), followed by c‐
NFAH at 2.9 ± 1.72 s (N = 10, range = 1–7). Both treatments
showed a significantly greater haemostatic effect than PCC
(9.8 ± 1.02 s [N = 15, range = 3–30]) and FTC (11.2 ± 0.49 s
[N = 10, range = 3–17]; Figure 1d). There was also a similar time
to haemostasis between the mild and severe models for c‐NFAH
and PCC treatments (Figure S2A).
Regarding applicability, PCC and FTC were applied by manual
pressure as indicated by the manufacturers. By contrast, NFAHs were
placed onto the wound without applying any additional pressure
(Figure 1b). This application procedure was sufficient to reach
haemostasis with NFAH treatment. After 24 hr, no presence of
rebleeding was found in any treated group, and only one FTC pad
was displaced in one animal.3.2 | NFAH has a favourable profile outcome for
tissue response and inflammatory features
Visual inspection of the wound 24 hr after the procedure in severe
model revealed no incidence of macroscopic haematoma in either c‐
NFAH or a‐NFAH groups. By contrast, perilesional haematoma was
present in rats treated with PCC and FTC (73.3% and 40%, respec-
tively; Figure 2a). Similar results were obtained in the mild model
(Figure S2B). Examples of haematoma with PCC and no haematoma
with a‐NFAH are shown in Figure 2b and 2c, respectively.
We also evaluated the presence of undesired adhesions to
surrounding healthy tissues at the time of sacrifice. Results showed
significant differences among groups, with rats treated with c‐NFAH
or a‐NFAH presenting similar results. Remarkably, some of these ani-
mals showed no adhesion at all, with most presenting only thin adhe-
sions. As expected, given that PCC an FTC have strong adhesive
properties (they have sealant indications), animals treated with PCC
and FTC consistently showed thicker adhesion to adjacent organs
(Figure 2d). Examples of high‐grade adhesion induced by PCC and
no adhesion by a‐NFAH are shown in Figure 2e and 2f, respectively.
We next measured the levels of inflammatory factors in blood (at
sacrifice) by ELISA, to test the inflammatory response at 24 hr follow-
ing surgery (minimum of N = 7 animals per group). Regarding CRP
levels, there were no significant differences between the a‐NFAH,
PCC, or FTC groups. However, CRP levels in the c‐NFAH group were
significantly higher than in the a‐NFAH (p < 0.01), PCC (p < 0.05), or
FTC (p < 0.001) groups (Figure 3a). By contrast, the PCC group had
significantly higher IL‐1β levels than the a‐NAFH or FTC groups
(p < 0.05 and p < 0.001, respectively), whereas no differences were
observed between c‐NAFH, a‐NAFH, and FTC groups (Figure 3b). Fur-
thermore, there were no significant differences in TNF‐α levels
between the a‐NAFH group and the other three groups. However,
the c‐NAFH and FTC groups presented significantly higher levels than
the PCC group (p < 0.01 and p < 0.05, respectively; Figure 3c).
Histopathological variables, including haemorrhage, inflammation,
and necrosis, were scored by blinded investigators according to the
criteria described in Section 2. Representative images of the different
grades of these variables are shown in Figure 4a. Both NFAH treat-
ments showed lower haemorrhage, inflammatory response, and necro-
sis than PCC or FTC treatment. Further, the PCC group displayed
FIGURE 2 Hepatic haematoma and
adhesion grade for different haemostatic
agents in rats subjected to long hepatic
incisions. (a) Percentage of rats with hepatic
haematoma 24 hr after treatment application.
(b,c) Representative images of haematoma
using PCC (b) and a‐NFAH (c). (d) Adhesion
grade of different haemostatic agents.
Adhesion in each sample was classified by a
score of 0–2: 0, no adhesion; 1, thin adhesions
separable by gravity; and 2, thick adhesions
not separable by gravity. (e,f) Representative
images of adhesion in long hepatic incisions
treated with PCC (e) and a‐NFAH (f). c‐NFAH:
cellularized‐nanostructurated fibrin‐agarose
hydrogel; a‐NFAH: acellular‐nanostructurated
fibrin‐agarose hydrogel; FTC: fibrinogen/
thrombin‐coated collagen pad (Tachosil®);
PCC: protein‐reactive polyethylene glycol‐
coated collagen pad (Hemopatch®) [Colour
figure can be viewed at wileyonlinelibrary.
com]
CAMPOS‐CUERVA ET AL. 669more overall haemorrhage than the other groups. Conversely, the c‐
NFAH treatment group presented the lowest percentage of animals
with haemorrhage at the microscopic level (40%), showing only mild
haemorrhage in some animals (Figure 4b). Moreover, only 10% of
the animals in the a‐NFAH group showed intense haemorrhage, which
was similar to the FTC group. Concerning inflammation, both NFAH
groups had the best profile, with only 10% of animals exhibiting
intense inflammation (in the c‐NFAH group). However, both PCC
and FTC treatments showed more than 30% of animals with intense
inflammation. A similar trend was found for necrosis. Accordingly,
the NFAH groups presented the highest percentage of absent and
mild necrosis, with no events of intense necrosis, whereas rats treated
with PCC and FTC presented a higher percentage of moderate and
intense necrosis.4 | DISCUSSION
In this study, we demonstrate the haemostatic effectiveness of a novel
nanostructured fibrin‐type VII agarose hydrogel, with (c‐NFAH) or
without (a‐NFAH) embedded allogeneic fibroblasts. We compared
the haemostatic features of NFAH with PCC and FTC, which are
widely used in clinical practice. Moreover, we performed a procedure
consisting of a short (0.5 cm) or long (1.5 cm) incision to create a mild
or severe surgical model of hepatic resection.In a preliminary mild model study, c‐NFAH showed greater
haemostatic ability than the commercially available PCC matrix,
prompting us to extend the study to a more severe model of hepatic
incision. We also included the a‐NFAH and FTC substrates in the
study. a‐NFAH was incorporated to assess whether the presence of
fibroblasts provided a significant improvement in haemostasis
(Costa‐Almeida, Soares, & Granja, 2017) against the hypothesis that
NFAH matrix could account for most of the haemostatic potential
of the pads. FTC was incorporated to compare NFAH with a
commercial haemostatic agent of similar composition. In this second
analysis, c‐NFAH and a‐NFAH showed significantly lower time to
haemostasis when compared with PCC and FTC; however, no
significant differences were found between c‐NFAH and a‐NFAH.
Interestingly, in our hepatic surgical model, better haemostasis was
reached using PCC than FTC, in line with a previous report (Lewis
et al., 2014).
In addition to time to haemostasis, we investigated other relevant
outcomes such as incidence of haematoma formation, rebleeding
and/or adhesions, levels of some inflammatory factors, and histology.
In contrast to the PCC and FTC treatments, both NFAH treatments
showed a complete absence of haematoma formation and a low
incidence of thick adhesions. These results might be due to a combi-
nation of the fast adherence of the NFAH pads, their lower time to
haemostasis and their easier applicability to the wound surface. Con-
trary to a previous study, PCC had a higher incidence of haematoma
FIGURE 3 Inflammation factor levels in rats subjected to long
hepatic incision after haemostatic treatment. (a) CRP, (b) IL‐1β, and
(c) TNF‐α blood levels measured by ELISA after 24 hr in rats with long
hepatic incision treated with c‐NFAH, a‐NFAH, PCC, or FTC. Data
represent mean ± SEM. Data were analysed using Kruskal–Wallis
analysis of variance test followed by Dunn's post hoc test (N = 7–15);
*p < 0.05; **p < 0.01; ***p < 0.001. c‐NFAH: cellularized‐
nanostructurated fibrin‐agarose hydrogel; a‐NFAH: acellular‐
nanostructurated fibrin‐agarose hydrogel; FTC: fibrinogen/thrombin‐
coated collagen pad (Tachosil®); PCC: protein‐reactive polyethylene
glycol‐coated collagen pad (Hemopatch®); CRP: C‐reactive protein;
IL‐1β: interleukin 1 beta; TNF‐α: tumour necrosis factor alpha
670 CAMPOS‐CUERVA ET AL.formation than FTC in our model (Lewis et al., 2014). Overall,
a‐NFAH was superior to the other groups regarding inflammatory
factors, with levels equal to or lower than those found with the com-
mercial products. However, c‐NFAH had significant higher CRP levels
than a‐NFAH, likely due to the presence of cells. Similarly, NFAH
treatment groups had lower grades of haemorrhage, inflammation,
and necrosis.
An additional advantage of NFAHs is the smaller adherent effect
on surrounding tissue in contrast with hemostats PCC and FTC. This
feature can be a great asset to certain types of surgeries.
Our novel NFAH matrix is composed of a nanostructured
fibrin‐type VII agarose hydrogel that is completely absorbable and
biodegradable and displays optimal biomechanical and rheological
properties (flexibility, elasticity, and mechanical strength), with no tis-
sue reactivity or antigenicity (Garzón et al., 2009; Fernández‐Valadés
Gámez et al., 2017). Agarose is a polysaccharide extracted from cer-
tain algae that, besides being an inert product from an immunological
perspective, offers natural adhesiveness. This feature, as well as the
high fibrin content (such that it does not rely on fibrinogen conversion
as FTC, for example), may contribute to the haemostatic effectiveness
of NFAH and the rapid sealing of damaged tissue.
We need to mention that, besides the fibrin, other agents used in
the formulation may contribute to the haemostatic effect of our
NFAH. Tranexamic acid is a procoagulant drug that has an
antifibrinolytic action and has been successfully used to reduce blood
loss in several types of surgery (Meng, Pan, Xiong, & Liu, 2018;
Queiroz et al., 2018; Suh, Kyung, Han, Cheong, & Lee, 2018; Zilinsky
et al., 2019). Indeed, it has been shown that the use of tranexamic acid
and fibrinogen reduces blood loss and improves coagulation measure-
ments in a porcine model of liver injury (Zentai et al., 2016). However,
the final content of tranexamic acid in the NFAH (1.6% or 8.3 mg) is
quite low compared with the concentrations used for topical applica-
tion (100–500 mg) or intravenously (1 g). Similarly, calcium chloride
accelerates fibrin polymerization and clot formation (Brass, Forman,
Edwards, & Lindan, 1978), and although it is used to stabilize the
matrix, we cannot exclude that the haemostatic effect of the NFAH
is enhanced by the presence of calcium.
Furthermore, NFAH has been used as a scaffolding matrix for
different artificial tissues, with excellent clinical results in terms of
safety thus far (ClinicalTrials.gov: NCT01765244).
The surgical model developed herein may not be absolutely
predictive for clinical use. Nevertheless, it does allow a standardized
evaluation of our novel hydrogel pad against two commercially
available haemostatic agents. As this study was designed as a proof‐
of‐concept, we chose rats as our first experimental model, mainly
due to their easy availability and handling and low cost. Further inves-
tigations are warranted to evaluate NFAH haemostatic effectiveness
in other surgical‐based experimental models. Indeed, studies to evalu-
ate long‐term safety and a method of NFAH preservation are currently
underway in our laboratory.
As mentioned, no optimal haemostatic agent exists to date, and
uncontrolled surgical bleeding remains an unmet clinical need. Any
improvement in terms of reduction of time to haemostasis and/or
FIGURE 4 Haemorrhage, inflammation, and
necrosis scores in rats subjected to long
hepatic incision treated with different
haemostatic agents. (a) Representative
histological images showing different grades
of haemorrhage, inflammation, and necrosis.
(b) Percentage of rats with haemorrhage (left),
inflammation (middle), and necrosis (right) in
long hepatic incision treated with PCC, FTC,
c‐NFAH, or a‐NFAH. Each sample was
classified as absent, mild, moderate, or intense
(see Table 1 for categorization). c‐NFAH:
cellularized‐nanostructurated fibrin‐agarose
hydrogel; a‐NFAH: acellular‐nanostructurated
fibrin‐agarose hydrogel; FTC: fibrinogen/
thrombin‐coated collagen pad (Tachosil®);
PCC: protein‐reactive polyethylene glycol‐
coated collagen pad (Hemopatch®) [Colour
figure can be viewed at wileyonlinelibrary.
com]
CAMPOS‐CUERVA ET AL. 671rebleeding, along with ease of use and applicability, could pose a huge
impact not only in hospital costs but also in patients' quality of life. We
show here that NFAH has excellent haemostatic and sealing
properties, and we believe that these results will pave the way for this
new product to be part of the arsenal of haemostatic agents in multi-
ple surgical procedures in the future.
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expression in cultured rat fibroblasts was determined by immunostain-
ing analysis. HaCat, an immortal keratinocyte cell line, was used as a
negative control. (C) Karyotype analysis of single cell‐dissociated
culture.
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between the mild and severe models for c‐NFAH and PCC treat-
ments. (A) Comparison of time to hemostasis for rats subjected to
short and long hepatic incision treated with PCC or c‐NFAH.
(N = 10). (B) Percentage of rats subjected to short incision with hepatic
hematoma 24 hours after treatment application. Abbreviations: c‐
NFAH, cellularized‐nanostructurated fibrin‐agarose hydrogel; PCC,
protein‐reactive polyethylene glycol‐coated collagen pad
(Hemopatch®).
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